Skip to content

Effectiveness of Unani add-on therapy in preventing the disease severity of COVID-19 infection

A study to assess the safety and efficacy of add-on Unani regimen in preventing the progression of severity of the disease in mild to moderate symptomatic COVID-19 RT-PCR positive cases

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2020/12/029575
Enrollment
100
Registered
2020-12-04
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere Health Condition 2: J09- Influenza due to certain identified influenza viruses

Interventions

Intervention1: Unani Decoction/ Joshanda add-on with Conventional Allopathic treatment: Unani Decoction twice daily orally Ingredients of Unani Decoction: 1. Behidana (Cydonia oblonga) 3 g, 2. Unnab

Sponsors

Central Council for Research in Unani Medicine
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. On the day of admission patients who have been tested positive with SARS-CoV2 virus through RT PCR 2. Patients with mild symptoms or Patients with moderate symptoms with respiratory rate 90%

Exclusion criteria

Exclusion criteria: 1. COVID-19 patients with symptoms classified as severe or critical. 2. Suspected COVID-19, not tested positive for COVID-19 by RT-PCR 3. Persons with severe primary respiratory disease or pneumonia 4. Pregnant and lactating women 5. Persons with severe illness such as Cancer, Heart Disease, Stroke, Mental disorder, etc., and who are considered to be excluded from the study as evaluated by the Investigators 6. COVID-19 positive cases simultaneously participating as subjects in the interventional arm of other COVID-19 clinical trials

Design outcomes

Primary

MeasureTime frame
- Duration of subsidence of fever, respiratory and other COVID-19 symptomsTimepoint: Day 0 to Day 14

Secondary

MeasureTime frame
â?¢ Time taken to get COVID-19 RT-PCR test negative â?¢ Incidence of patients progressing to next stage with regards to severity â?¢ Duration of Hospital and ICU stay â?¢ The use of supplementary Oxygen (Days for which oxygen was required) â?¢ Any clinical reported adverse events reported (and whether the drug had to be discontinued due to the adverse effect) â?¢ Quality of life scores on WHO Timepoint: Day 14

Countries

India

Contacts

Public ContactDr Tamanna Nazli

Vardhman Mahavir Medical College & Safdarjung Hospital

dr.rohitkumar@mail.com9911218081

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026